|
 |
RALPH MAKAR
was
appointed as our President and Chief
Executive Officer and named as
director on October 1, 2007. From
December 2005 until joining Bioject,
Mr. Makar was engaged in a number of
entrepreneurial ventures, which
included consulting, specialty
pharmaceuticals and technology. Mr.
Makar brings marketing and general
management expertise, having worked
with biotech, specialty and niche
pharmaceutical brands. From 2003 to
2005, Mr. Makar served as Vice
President and General Manager of the
Therapeutics Business Unit at Berlex
Labs (“Berlex”), the U.S. Division
of Schering AG, which later became
Bayer Health Care. From 2000 to
2003, he served as Vice President of
Marketing for the Therapeutics
Business Unit at Berlex. Before
joining Berlex, Mr. Makar held a
number of strategic and tactical
marketing positions with increasing
responsibility at Novartis
(initially with Ciba-Geigy
pre-merger) and Parke-Davis
(Division of Warner-Lambert which
post-acquisition became Pfizer),
both pharmaceutical companies. Mr.
Makar earned a B.S. in Pharmacy from
Rutgers College of Pharmacy in
Piscataway, New Jersey and an M.B.A.
from Columbia Business School in New
York, New York.
|
 |
CHRISTINE FARRELL
joined Bioject in February
1997 as Assistant
Controller. Ms. Farrell was
promoted to Corporate
Controller in September 1999
and to Vice President of
Administration and Corporate
Controller in July 2004.
Effective May 3, 2006, Ms.
Farrell assumed the Chief
Financial Officer
responsibilities and her
title became Vice President
of Finance. In March 2007,
Ms. Farrell, along with Mr.
Stout, became a member of
the Executive Committee,
which serves the role of our
Chief Operating Officer.
Prior to joining Bioject,
Ms. Farrell held accounting
and financial management
positions with Spar-Tek
Industries, a manufacturer
of high quality and cutting
edge technology for the
plywood industry, and Action
Machinery, a seller of new
and used robotic machine
tools and equipment. Ms.
Farrell holds a B.A. degree
in Accounting from the
University of Washington and
a Masters of Management from
Willamette University in
Salem, Oregon. |
 |
RICHARD STOUT, M.D.
joined Bioject in April 1994 as
Director of Clinical and Regulatory Affairs. He was promoted
to Vice President of Clinical Affairs in December 1994 and
to Executive Vice President and Chief Medical Officer in
March 2007. In March 2007, Mr. Stout, along with Ms.
Farrell, became a member of the Executive Committee, which
serves the role of our Chief Operating Officer. From 1992 to
1993 he was the Director of Clinical and Regulatory Affairs
at EndoVascular Instruments, Inc., a developer of surgical
devices and methods for endarterectomy and intraluminal
graft placement. Dr. Stout acted as the Manager of
Tachycardia Clinical Studies at Telectronics Pacing Systems,
an international medical device company involved in
manufacturing and distributing cardiac pacemakers and
implantable defibrillators, from 1990 to 1992. From 1987 to
1989, Dr. Stout was Director of Medical Programs at
Biotronic Inc., also a manufacturer and distributor of
implantable cardiac pacemakers. |
|
|
JERALD
S. COBBS has served as a director since March 2006 and as
Chairman of the Board from October 2006 until February 2008. In
March 2007, Mr. Cobbs served as our Interim President and Chief
Executive Officer. Mr. Cobbs is Chief Commercialization Officer
of the Cancer Prevention Research Institute of Texas (CPRIT).
From 2001 to 2009, Mr. Cobbs was Managing Director of LOF
Partners, LLC, an investment management fund. Mr. Cobbs has more
than twenty five years experience in the health sciences and
biotechnology industries. He presently serves on the board of
directors of Cedarburg Pharmaceuticals. He is a board observer
to Optiscan Biomedical Corporation and Functional Genetics, Inc.
Mr. Cobbs previously served as the Assistant Director of
Technology Development at the University of Texas – M.D.
Anderson Cancer Center, in the Houston Medical Center. During
his tenure at M.D. Anderson Cancer Center, he helped form two
molecular therapy companies: Introgen Therapeutics (NASDAQ: INGN),
a pioneer in gene-based therapies for a variety of cancers based
in Austin, Texas and Rgene Therapeutics, which was sold to
Targeted Genetics, Inc. (NASDAQ: TGEN). Mr. Cobbs was also
Chairman and Chief Executive Officer of Quantitative Diagnostic
Laboratories, a cancer diagnostic and image analysis company
based in Chicago, IL. Mr. Cobbs received his M.B.A. from the
University of Houston.
EDWARD L. FLYNN
was elected a director in November 2007. Mr. Flynn also served
as a member of our Board from 1999 to 2004. Since 1972, Mr.
Flynn has been owner and Chief Executive Officer of Flynn Meyer
Company, a restaurant industry management company. From 1958 to
1972, Mr. Flynn was a securities broker with Merrill Lynch
Pierce Fenner and Smith. He serves as a member of the board of
directors and the Chief Financial Officer of Citri-Lite Co.
Inc., a soft drink company. He also serves as a member of the
board of directors of TGCI Industries, a geophysical service
company primarily conducting three dimensional seismic surveys
for companies engaged in oil and gas exploration. He is a
director of Supreme Industries, a manufacturer of specialized
vehicles and truck bodies, and Chase Packaging, a food packaging
company. He also serves on the board of trustees of Fordham Prep
in New York City.
DAVID S. TIERNEY,
M.D. has served as a director since June 2007 and as
Chairman from February 2008 to January 2010. Dr. Tierney is
President and Chief Operating Officer for Oceana Therapeutics
Inc., a specialty pharmaceutical company. From August 2000 to
April 2007, Dr. Tierney has served as the President, Chief
Executive Officer and Director of Valera Pharmaceuticals, Inc.,
a specialty pharmaceutical company, until it was acquired by
Indevus Pharmaceuticals, Inc (NASDAQ: IDEV). From January 2000
to August 2000, Dr. Tierney served as President of Biovail
Technologies, a division of Biovail Corporation, a Canadian drug
delivery company, where he was responsible for all of Biovail’s
research and development, regulatory and clinical activities.
From March 1997 to January 2000, Dr. Tierney was Senior Vice
President of Drug Development at Roberts Pharmaceutical
Corporation, where he was responsible for all research and
development activities, and for drug development, medical
affairs, worldwide regulatory affairs and chemical process
development, as well as being part of the executive management
team. From December 1989 to March 1997, Dr. Tierney was employed
by Élan Corporation, a pharmaceutical company, in a variety of
management positions. Dr. Tierney received his medical degree
from the Royal College of Surgeons in Dublin, Ireland and was
subsequently trained in internal medicine. Dr. Tierney is a
director of NexMed, Inc (NASDAQ: NEXM) and Catalyst
Pharmaceutical Partners (NASDAQ: CPRX).
AL HANSEN
joined the Board as a director in December 2009 and as
Chairman since January 2010. Mr. Hansen has been a Managing
Director of Signet Healthcare Partners, since 2001. Mr. Hansen
has over 20 years of private equity investment experience. He
was Chairman and interim CEO of Questcor Pharmaceuticals and
currently serves as a Director of BioPro Pharmaceutical,
Cedarburg Pharmaceuticals, LearnWright, and Malladi Drugs and
Pharmaceuticals. Mr. Hansen’s previous experience includes
serving as a principal of Darby Overseas Investments Ltd., a
private equity firm with a focus on emerging markets and as
Director of Corporate Finance at the U.S. Treasury Department.
Early in his career, Mr. Hansen was an investment banker with
Dillon Read & Co. Inc., focusing on mergers and acquisitions and
an investment banker at E.F. Hutton & Co. Mr. Hansen also served
in the U.S. Army as an Infantry and Special Forces officer.
Mr. Hansen has a B.A. from Princeton University and a Masters of
Business Administration from the Wharton School, University of
Pennsylvania.
MARK LOGOMASINI joined the
Board as a director in December 2009. Mr. Logomasini is the
Director of Business Development for the Government Sector Group
of SAFC/Sigma-Aldrich Corporation. He is responsible for
developing the strategic plan for Federal programs and
coordinating business development activities across SAFC
business units. Mark Logomasini was formerly a Founder and the
Chief Financial Officer/VP Business Development for Molecular
Medicine BioServices, Inc., a contract biologics development and
manufacturing organization acquired by Sigma-Aldrich in 2007. In
that position, he had overall responsibility for finance during
the company’s turnaround to profitability. He developed the
capital structure and led the team that secured more than a
dozen vaccine and therapeutic manufacturing awards from the
Department of Defense and National Institute of Allergy and
Infectious Diseases. Prior to Molecular Medicine, Mark
Logomasini was the President of Western Separations, a
bioprocess equipment and sales company which he sold in 2001. He
holds a B.Sc. in Chemical Engineering from the Missouri School
of Mines and an MBA (with Honors) from the Merage School of
Management at the University of California – Irvine.
|
